Jon Iredell profile

Jon Iredell

Jon is an Infectious Disease Physician and Microbiologist who divides his time between Westmead Hospital in a combined Infectious Diseases and Microbiology Department and his research which is supported by the NHMRC at the University of Sydney.

His major interests are in critical infection, including the study of bacterial septic shock, and in bacterial genetics and ecology. Formal affiliations are (1) Conjoint Professor of Medicine and Microbiology, Sydney Medical School The University of Sydney/The Westmead Institute for Medical Research and the Marie Bashir Institute, (2) Senior Staff Specialist, Western Sydney and Westmead Hospital and Deputy Director Microbiology, Pathology West (NSW Pathology) and Institute of Clinical Pathology and Medical Research, (3) Director, Centre for Infectious Diseases and Microbiology at Westmead Institute for Medical Research. List of publications.

January 20, 2023
PhageBusiness ModelsSustainability
Phage Therapy Polyclonal Bacteraemia Staphylococcus aureus

Staphylococcus aureus is a leading cause of bacteraemia and endocarditis in which intraclonal genetic variation, but not true polyclonal bacteraemia, is well documented. We describe a case of 36-year-old women with simultaneous and persistent bacteremia from two strains of Staphylococcus aureus that probably would have gone unrecognised because of the identical antibiotic profiles if had we not used bacteriophage susceptibility (“phage typing”) to further characterise the strains. In this patient, the dual bacteraemia was followed months later by another bacteraemia that likely would have been deemed a relapse of the original infection, except that we used similar methods to identify a third and unrelated strain. Our patient eventually responded well to antibiotics, and her bacteriophage therapy probably contributed little to that recovery. However, bacteriophage therapy required that we identify the strain of S. aureus causing her bacteraemia, and that requirement led directly to our identification of dual strains with identical antibiotic susceptibilities. Because of this experience, we alert other clinicians to the possibility of polyclonal infections with S. aureus. When bacteraemia is suspected, clinicians often pick a single colony or a few colonies from the original culture because prompt identification of the organism is critical and this practice provides a faster turnaround time. We caution that it might not identify different strains with different antibiotic sensitivities when polyclonal infections are present.

Annals of Internal Medicine
News | August 31, 2022
Phage Therapy
Academics plan to roll out therapy widely in Australia: Researchers at the University of Sydney, Western Sydney Local Health District and the Westmead Institute for Medical Research are developing a therapeutic solution to antimicrobial resistance that predates the discovery and wide usage of antibiotics… [Link to Paper](https://www.escmid.org/fileadmin/src/media/PDFs/1Dates_Events/event_flyers/ESGNTA_Course22_web.pdf)
News | August 17, 2022
Phage Therapy
An expert team, led by Director of the Centre of Infectious Diseases and Microbiology at the Westmead Institute for Medical Research (WIMR) Professor Jon Iredell, is developing a key alternative to antibiotics and central to the treatment are phages…
Publication | June, 2022
Publication | February, 2021
Publication | January, 2020
AbstractPhage Therapy
Publication | November, 2020
PediatricsPhage TherapyClinical trialResearch paper
Publication | August, 2021
Clinical trialPediatricsImmune responsePhage Therapy
Publication | December, 2020
Phage VirulenceAntibiotic synergyResearch paper
Publication | April, 2020
Review paperPhage Therapy
Publication | October, 2021
Review paperPhage TherapyPediatrics
© 2023 Phage Australia